You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
基石藥業(02616.HK)續漲13%曾逼近逾兩年前所創紀錄高位 交投活躍
與輝瑞在中國開發勞拉替尼的基石藥業(02616.HK)股價連續第二天探頂,最多急漲13%高見16.78元,接近2019年4月及3月所造上市高位16.9元遇壓,現造16.24元,續漲13%,成交進一步增至1,605萬股,爲九個月來最多,涉資2.53億元。

基石藥業日前公佈,與輝瑞(PFE.US)雙方將於大中華地區在c-rosoncogene1(ROS1)陽性晚期非小細胞癌(NSCLC)中共同開發勞拉替尼(lorlatini)。該項在中國即將開展ROS1陽性肺癌關鍵臨牀研究將是lorlatinib在該靶點的全球首次關鍵性研究。這是繼去年達成戰略合作後,雙方合作進一步深化。lorlatinib是一種具中樞神經系統穿透力的針對ROS1及間變性淋巴瘤激(酉每)(ALK)的第三代酪氨酸激(酉每)抑制劑。輝瑞也在中國開展lorlatinib針對ALK陽性肺癌的多項臨牀研究,並於今年3月遞交治療ALK陽性晚期NSCLC患者新藥上市申請。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account